5. 2 ” Farmakokinetiske egenskaber ”), vurderes den potentielle risiko for mennesker dog som værende begrænset.
However, based on the minimal extent of pimecrolimus absorption after topical application of < Invented Name >, (see Section 5.2 “Pharmacokinetic properties”), the potential risk for humans is considered limited.